MDMA-assisted therapy for PTSD heads toward FDA review as panel weighs trial evidence, bias concerns, and allegations

MDMA-assisted therapy for PTSD could be headed toward FDA approval after an FDA advisory panel reviews the evidence. The treatment pairs MDMA dosing with talk therapy, with trial claims of rapid and lasting reductions in PTSD symptoms. The interview highlights two competing realities: the data looks promising, but there are credible concerns about trial validity. One major issue is that participants and staff may have been able to tell whether they received MDMA or a placebo, which could bias outcomes, alongside questions about methods and long-term data. Recent controversy adds more pressure on the FDA decision. Reports allege that some therapists or investigators may have encouraged favorable reporting and failed to capture adverse events, while Lykos Therapeutics disputes the allegations. The FDA aims to make a decision by early August.